

MARGENZA® (margetuximab-cmkb) **Medication Precertification Request**

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

1-888-267-3277

For Medicare Advantage Part B: (All fields must be completed and legible for precertification review.) **Please Use Medicare Request Form** Please indicate: Start of treatment: Start date ____/ Continuation of therapy: Date of last treatment ____/ Precertification Requested By: Eav.

| i recertification requested | | | 1 Hone | | ı ax | |
|---|---|---|---|----------------------------------|-----------------------------------|------|
| A. PATIENT INFORMATION | | | | | | |
| First Name: | | | Last Name: | | | |
| Address: | | | City: | | State: | ZIP: |
| Home Phone: Worl | | R Phone: | | Cell Phone: | | • |
| DOB: | | | Email: | | | |
| Current Weight: | lbs orkgs | Height: | inches or | cms | } | |
| B. INSURANCE INFORMATION | | | | | | |
| Aetna Member ID #: | | Does patient have other coverage? ☐ Yes ☐ No | | | | |
| Group #: | | If yes, provide ID#: Carrier Name: | | | | |
| Insured: | | Insured: | | | | |
| Medicare: ☐ Yes ☐ No If yes, provide ID #: Medicaid: ☐ Yes ☐ No If yes, provide ID #: | | | | | | |
| C. PRESCRIBER INFORMATION | | | | | | |
| First Name: | | Last Name: | | (Check One): M.D. D.O. N.P. P.A. | | |
| Address: | | <u>.</u> | City: | | State: | ZIP: |
| Phone: | Fax: | St Lic #: | NPI #: | DEA #: | UF | PIN: |
| Provider Email: | | Office Contact Nan | ne: | | Phone: | |
| Specialty (Check one): Oncologist Other: | | | | | | - |
| D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION | | | | | | |
| ☐ Outpatient Infusion Cente Center Name: ☐ Home Infusion Center | Phone:PT): pargetuximab-cmkb) Dos N – Please indicate primary | se: | Name: Address: Phone: Frequerany other where applicable and the second | ffice [rmacy [mency: | ☐ Retail Pharm ☐ Other: Fax: PIN: | nacy |
| G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests. | | | | | | |
| For Initiation Requests (clinical documentation required for all requests): Breast cancer Please indicate the clinical setting in which the requested drug will be used: Recurrent unresectable disease Metastatic disease The disease had no response to preoperative systemic therapy Other Please indicate the patient's the human epidermal growth factor receptor 2 (HER2) status: HER2 positive HER2 negative Unknown | | | | | | |
| ☐ Yes ☐ No Will the requests ☐ Yes ☐ No Is there evidently a support of the continuation of the continuat | rested drug be used in cor ent received treatment wit (clinical documentation | mbination with chemo h two or more prior re required for all requ | therapy? egimens? uests): | | ETTE Hogalive | |
| H. ACKNOWLEDGEMENT | | | | | | |
| Request Completed By (Signature Required): Date:/ | | | | | | |
| Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive | | | | | | |

any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent

insurance act, which is a crime and subjects such person to criminal and civil penalties. The plan may request additional information or clarification, if needed, to evaluate requests.